206 related articles for article (PubMed ID: 31484660)
41. Investigation of the prevalence and number of aberrant crypt foci associated with human colorectal neoplasm.
Sakai E; Takahashi H; Kato S; Uchiyama T; Hosono K; Endo H; Maeda S; Yoneda M; Taguri M; Nakajima A
Cancer Epidemiol Biomarkers Prev; 2011 Sep; 20(9):1918-24. PubMed ID: 21750169
[TBL] [Abstract][Full Text] [Related]
42. Berberine versus placebo for the prevention of recurrence of colorectal adenoma: a multicentre, double-blinded, randomised controlled study.
Chen YX; Gao QY; Zou TH; Wang BM; Liu SD; Sheng JQ; Ren JL; Zou XP; Liu ZJ; Song YY; Xiao B; Sun XM; Dou XT; Cao HL; Yang XN; Li N; Kang Q; Zhu W; Xu HZ; Chen HM; Cao XC; Fang JY
Lancet Gastroenterol Hepatol; 2020 Mar; 5(3):267-275. PubMed ID: 31926918
[TBL] [Abstract][Full Text] [Related]
43. The Efficacy of Aspirin in Preventing the Recurrence of Colorectal Adenoma: a Renewed Meta-Analysis of Randomized Trials.
Zhao TY; Tu J; Wang Y; Cheng DW; Gao XK; Luo H; Yan BC; Xu XL; Zhang HL; Lu XJ; Wang YJ
Asian Pac J Cancer Prev; 2016; 17(5):2711-7. PubMed ID: 27268656
[TBL] [Abstract][Full Text] [Related]
44. Aspirin for the chemoprevention of colorectal adenomas: meta-analysis of the randomized trials.
Cole BF; Logan RF; Halabi S; Benamouzig R; Sandler RS; Grainge MJ; Chaussade S; Baron JA
J Natl Cancer Inst; 2009 Feb; 101(4):256-66. PubMed ID: 19211452
[TBL] [Abstract][Full Text] [Related]
45. A multicenter study of prevalence and risk factors for aberrant crypt foci.
Mutch MG; Schoen RE; Fleshman JW; Rall CJ; Dry S; Seligson D; Charabaty A; Chia D; Umar A; Viner J; Hawk E; Pinsky PF
Clin Gastroenterol Hepatol; 2009 May; 7(5):568-74. PubMed ID: 19418605
[TBL] [Abstract][Full Text] [Related]
46. Suppressive effect of aspirin on aberrant crypt foci in patients with colorectal cancer.
Shpitz B; Klein E; Buklan G; Neufeld D; Nissan A; Freund HR; Grankin M; Bernheim J
Gut; 2003 Nov; 52(11):1598-601. PubMed ID: 14570729
[TBL] [Abstract][Full Text] [Related]
47. The effect of aspirin in the recurrence of colorectal adenomas: a meta-analysis of randomized controlled trials.
Gao F; Liao C; Liu L; Tan A; Cao Y; Mo Z
Colorectal Dis; 2009 Nov; 11(9):893-901. PubMed ID: 19055515
[TBL] [Abstract][Full Text] [Related]
48. Randomized phase II trial of sulindac, atorvastatin, and prebiotic dietary fiber for colorectal cancer chemoprevention.
Limburg PJ; Mahoney MR; Ziegler KL; Sontag SJ; Schoen RE; Benya R; Lawson MJ; Weinberg DS; Stoffel E; Chiorean M; Heigh R; Levine J; Della'Zanna G; Rodriguez L; Richmond E; Gostout C; Mandrekar SJ; Smyrk TC;
Cancer Prev Res (Phila); 2011 Feb; 4(2):259-69. PubMed ID: 21209397
[TBL] [Abstract][Full Text] [Related]
49. Prevention by daily soluble aspirin of colorectal adenoma recurrence: 4-year results of the APACC randomised trial.
Benamouzig R; Uzzan B; Deyra J; Martin A; Girard B; Little J; Chaussade S;
Gut; 2012 Feb; 61(2):255-61. PubMed ID: 21890814
[TBL] [Abstract][Full Text] [Related]
50. Prevention by aspirin and its combination with alpha-difluoromethylornithine of azoxymethane-induced tumors, aberrant crypt foci and prostaglandin E2 levels in rat colon.
Li H; Schut HA; Conran P; Kramer PM; Lubet RA; Steele VE; Hawk EE; Kelloff GJ; Pereira MA
Carcinogenesis; 1999 Mar; 20(3):425-30. PubMed ID: 10190557
[TBL] [Abstract][Full Text] [Related]
51. The efficacy of a leukotriene receptor antagonist in the treatment of human rectal aberrant crypt foci: a nonrandomized, open-label, controlled trial.
Higurashi T; Arimoto J; Ashikari K; Takatsu T; Misawa N; Yoshihara T; Matsuura T; Fuyuki A; Ohkubo H; Nakajima A
BMC Cancer; 2020 Aug; 20(1):770. PubMed ID: 32807113
[TBL] [Abstract][Full Text] [Related]
52. APACC, a French prospective study on aspirin efficacy in reducing colorectal adenoma recurrence: design and baseline findings.
Benamouzig R; Yoon H; Little J; Martin A; Couturier D; Deyra J; Coste T; Chaussade S;
Eur J Cancer Prev; 2001 Aug; 10(4):327-35. PubMed ID: 11535875
[TBL] [Abstract][Full Text] [Related]
53. A randomized, double-blind, placebo-controlled phase 3 skin cancer prevention study of {alpha}-difluoromethylornithine in subjects with previous history of skin cancer.
Bailey HH; Kim K; Verma AK; Sielaff K; Larson PO; Snow S; Lenaghan T; Viner JL; Douglas J; Dreckschmidt NE; Hamielec M; Pomplun M; Sharata HH; Puchalsky D; Berg ER; Havighurst TC; Carbone PP
Cancer Prev Res (Phila); 2010 Jan; 3(1):35-47. PubMed ID: 20051371
[TBL] [Abstract][Full Text] [Related]
54. A randomized trial of rofecoxib for the chemoprevention of colorectal adenomas.
Baron JA; Sandler RS; Bresalier RS; Quan H; Riddell R; Lanas A; Bolognese JA; Oxenius B; Horgan K; Loftus S; Morton DG;
Gastroenterology; 2006 Dec; 131(6):1674-82. PubMed ID: 17087947
[TBL] [Abstract][Full Text] [Related]
55. Cyclooxygenase-2 expression and recurrence of colorectal adenomas: effect of aspirin chemoprevention.
Benamouzig R; Uzzan B; Martin A; Deyra J; Little J; Girard B; Chaussade S;
Gut; 2010 May; 59(5):622-9. PubMed ID: 20427397
[TBL] [Abstract][Full Text] [Related]
56. Follow-up of tumor development in the colons of living rats and implications for chemoprevention trials: assessment of aspirin-difluoromethylornithine combination.
Raul F; Gosse F; Osswald AB; Bouhadjar M; Foltzer-Jourdainne C; Marescaux J; Soler L
Int J Oncol; 2007 Jul; 31(1):89-95. PubMed ID: 17549408
[TBL] [Abstract][Full Text] [Related]
57. Aspirin helps prevent recurring colorectal adenomas--folic acid does not.
Lundberg GD
Medscape J Med; 2008 Mar; 10(3):69. PubMed ID: 18449348
[No Abstract] [Full Text] [Related]
58. Folic acid supplementation inhibits recurrence of colorectal adenomas: a randomized chemoprevention trial.
Jaszewski R; Misra S; Tobi M; Ullah N; Naumoff JA; Kucuk O; Levi E; Axelrod BN; Patel BB; Majumdar AP
World J Gastroenterol; 2008 Jul; 14(28):4492-8. PubMed ID: 18680228
[TBL] [Abstract][Full Text] [Related]
59. Chemoprevention of colorectal cancer.
Niitsu Y; Takayama T; Miyanishi K; Nobuoka A; Hayashi T; Kukitsu T; Takanashi K; Ishiwatari H; Abe T; Kogawa T; Takahashi M; Matsunaga T; Kato J
Cancer Chemother Pharmacol; 2004 Sep; 54 Suppl 1():S40-3. PubMed ID: 15309513
[TBL] [Abstract][Full Text] [Related]
60.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
